secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001193125-24-137210
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences Q1 net loss $0.16/shr; cash $30.4M; FB102 SAD completed, MAD ongoing
--------------------------------------------------------------------------------

- Net loss $7.4M ($0.16/shr) vs $6.8M ($0.32/shr) in Q1 2023; weighted avg shares 46.1M (incl. pre-funded warrants).
- R&D expense $4.4M (down $0.4M); G&A $3.5M (up $1.4M on legal/professional costs).
- Cash & equivalents $30.4M at Mar 31, 2024, down from $37.1M at Dec 31, 2023.
- FB102 Phase 1 SAD completed; MAD cohorts expected to complete mid-2024; patient studies planned before year-end.
- Company updated corporate presentation (Exhibit 99.2) for investor meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/0001193125-24-137210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524137210/d825808d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-137210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer